At the time of writing, Lexaria Bioscience Corp [LEXX] stock is trading at $1.04, down -0.95%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The LEXX shares have gain 8.23% over the last week, with a monthly amount drifted -3.26%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
For the past year, the stock price of Lexaria Bioscience Corp fluctuated between $0.92 and $4.38. Lexaria Bioscience Corp [NASDAQ: LEXX] shares were valued at $1.04 at the most recent close of the market.
Analyzing the LEXX fundamentals
According to Lexaria Bioscience Corp [NASDAQ:LEXX], the company’s sales were 0.53M for trailing twelve months, which represents an 20.00% jump. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -17.85%, Pretax Profit Margin comes in at -17.85%, and Net Profit Margin reading is -17.84%. To continue investigating profitability, this company’s Return on Assets is posted at -1.08, Equity is -1.07 and Total Capital is -1.37. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.9497 points at the first support level, and at 0.8593 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.1152, and for the 2nd resistance point, it is at 1.1903.
Ratios To Look Out For
It is important to note that Lexaria Bioscience Corp [NASDAQ:LEXX] has a current ratio of 4.24. Further, the Quick Ratio stands at 4.24, while the Cash Ratio is 3.55. Considering the valuation of this stock, the price to sales ratio is 38.23, the price to book ratio is 2.54.
Transactions by insiders
Recent insider trading involved CHRISTOPHER RICHARD, Chief Executive Officer, that happened on Dec 03 ’24 when 27172.0 shares were purchased. Chief Executive Officer, CHRISTOPHER RICHARD completed a deal on Dec 02 ’24 to buy 22828.0 shares. Meanwhile, Director TURKEL CATHERINE C. bought 1600.0 shares on Aug 12 ’24.
